A randomized, double-blind, double-simulation controlled trial of Sang-qi Granula on treating of vascular endothelial function of primary hypertension

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1800016427

Enrollment

Unknown

Registered

2018-06-01

Start date

2018-06-20

Completion date

Unknown

Last updated

2018-06-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

primary hypertension

Interventions

Traditional Chinese medicine group:Traditional Chinese medicine group will be given San-qi Granula and Cozaar placebo for 2 months, Sang-Qi granule will be taken every morning and evening, 10g every t

Western medicine group:Western medicine group will be given Cozaar and San-qi Granula placebo for 2 months, and Cozaar will be taken 50mg every morning, Sang-Qi granule placebo will be taken every mor

Traditional Chinese medicine + Western medicine group:Traditional Chinese medicine+ Western medicine group will be given San-qi Granula and Cozaar for 2 months, Sang-Qi granule will be taken every mor

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Understand the process of this testvolunteer to take part in this test and sign informed consent; 2. Conforms to the diagnosis standard:Primary hypertension grade 1-2; 3. No combined use of Western medicine for antihypertensive drugs; 4. Aged between 18-70 years; If any of the above answers is "no", this participant cant participate in this clinical trials.

Exclusion criteria

Exclusion criteria: 1. Uncooperative; 2. Secondary hypertension; 3. Liver dysfunctionALT and AST are more than 2 times the normal upper limit; 4. Renal dysfunctionSerum creatinine is more than 133mmol/L; 5. Severe chronic gastrointestinal diseases; 6. Active myocarditis or pericarditis; 7. Unstable angina pectoris in 2 weeks; 8. Planned surgery for heart surgery; 9. Significant hematological diseases; 10. Allergy to experimental drugs; 11. Mental illness, Abuse of drugs or other items; 12. Surgery, severe trauma and other stress conditions; 13. Lactation or gestation or prepare to Pregnant women; If any of the above answers is "yes", this participant cant participate in this clinical trials.

Design outcomes

Primary

Measure	Time frame
Blood pressure;vascular endothelial function;echocardiogram;	—

Countries

China

Contacts

Public ContactLi Lin

China-Japanese Friendship Hospital

lilinxcy@126.com+86 18600285198

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 28, 2026